These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31319390)

  • 1. PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
    Magnani CJ; Li K; Seto T; McDonald KM; Blayney DW; Brooks JD; Hernandez-Boussard T
    J Natl Compr Canc Netw; 2019 Jul; 17(7):795-803. PubMed ID: 31319390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
    Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
    J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
    Li J; Berkowitz Z; Hall IJ
    J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
    Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
    JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
    Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
    J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
    Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
    BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
    Schmanke K; Okut H; Ablah E
    Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
    Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
    Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
    Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
    Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.